Kenvue Inc. $KVUE Shares Sold by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management cut its Kenvue stake by 49.8% in the second quarter, selling 3.19 million shares and retaining 3.22 million shares worth approximately $61.5 million. Institutional investors collectively own 97.64% of the company.
• Kenvue reported second-quarter sales of $3.96 billion, up 3% year over year, and adjusted EPS of $0.31, although both figures slightly missed analyst estimates. Inflation, tariffs and currency costs pressured margins.
• The stock was trading near $19.22, while analysts maintained an overall “Hold” view with an average price target of $19.36. Kenvue’s quarterly dividend remains $0.21 per share, implying a 4.4% annualized yield.

Assenagon Asset Management S.A. decreased its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 49.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,216,202 shares of the company's stock after selling 3,187,374 shares during the quarter. Assenagon Asset Management S.A. owned about 0.17% of Kenvue worth $61,462,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. CoreCap Advisors LLC lifted its holdings in Kenvue by 64.9% during the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company's stock worth $29,000 after buying an additional 591 shares during the last quarter. Montag A & Associates Inc. lifted its position in shares of Kenvue by 6.3% during the 1st quarter. Montag A & Associates Inc. now owns 10,156 shares of the company's stock worth $175,000 after buying an additional 600 shares during the last quarter. Cornerstone Wealth Group LLC boosted its holdings in shares of Kenvue by 5.9% in the 1st quarter. Cornerstone Wealth Group LLC now owns 10,810 shares of the company's stock valued at $187,000 after buying an additional 606 shares in the last quarter. Physician Wealth Advisors Inc. grew its position in shares of Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company's stock valued at $26,000 after buying an additional 618 shares during the last quarter. Finally, Mill Creek Capital Advisors LLC boosted its stake in Kenvue by 0.6% in the fourth quarter. Mill Creek Capital Advisors LLC now owns 124,213 shares of the company's stock valued at $2,143,000 after acquiring an additional 701 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue News Summary

Here are the key news stories impacting Kenvue this week:

• Positive Sentiment: Second-quarter net sales rose 3.0% year over year to $3.96 billion, supported by higher prices and volumes. Organic sales increased 1.6%, with growth across Self Care, Skin Health and Beauty, and Essential Health. Kenvue Posts Higher Profit, Sales as Turnaround Continues
• Positive Sentiment: Net income increased to $456 million from $420 million a year earlier, while adjusted diluted EPS reached $0.31 versus $0.29 in the prior-year quarter. Six-month operating cash flow was $1.2 billion and free cash flow was $1.0 billion. Kenvue Q2 net sales rise 3% as diluted EPS hits 24 cents
• Neutral Sentiment: The Kimberly-Clark transaction remains expected to close in the fourth quarter of 2026, subject to regulatory approvals and customary conditions. Kenvue is withholding forward guidance because of the pending deal, limiting visibility for investors. How Reddit and Wall Street See Kenvue as Buyout Nears
• Negative Sentiment: Adjusted EPS of $0.31 fell short of the $0.32 consensus estimate, while revenue of $3.96 billion was slightly below the $3.97 billion forecast. The miss was unusual for Kenvue and contributed to the recent decline in the stock. Kenvue misses quarterly estimates as inflation, tariffs squeeze margins
• Negative Sentiment: Margins narrowed as inflation, tariffs and currency-related costs offset part of the benefit from pricing and volume gains, raising concerns about near-term profitability and the company’s turnaround execution. KVUE Q2 Earnings Miss Estimates as Margins Narrows Sales Rise

Kenvue Stock Up 0.2%

KVUE stock opened at $19.22 on Friday. Kenvue Inc. has a one year low of $14.02 and a one year high of $21.95. The company has a 50 day moving average price of $18.77 and a two-hundred day moving average price of $18.09. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98. The stock has a market capitalization of $36.91 billion, a P/E ratio of 22.09, a PEG ratio of 1.46 and a beta of 0.47.

Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $0.31 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.01). Kenvue had a net margin of 10.76% and a return on equity of 21.17%. The business had revenue of $3.96 billion during the quarter, compared to analyst estimates of $3.97 billion. During the same quarter in the previous year, the company posted $0.29 earnings per share. The business's revenue for the quarter was up 3.0% compared to the same quarter last year. As a group, sell-side analysts expect that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 26th. Stockholders of record on Wednesday, August 12th will be issued a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a dividend yield of 4.4%. The ex-dividend date is Wednesday, August 12th. This is an increase from Kenvue's previous quarterly dividend of $0.21. Kenvue's payout ratio is currently 97.65%.

Analysts Set New Price Targets

A number of analysts have recently commented on KVUE shares. Citigroup cut their target price on Kenvue from $20.00 to $19.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 15th. Weiss Ratings upgraded Kenvue from a "hold (c-)" rating to a "hold (c)" rating in a research note on Monday, June 15th. Zacks Research lowered Kenvue from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 7th. Wall Street Zen cut Kenvue from a "buy" rating to a "hold" rating in a research note on Saturday. Finally, Barclays increased their price objective on Kenvue from $18.00 to $19.00 and gave the company an "equal weight" rating in a report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $19.36.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source